Congress Asset Management Co. Sells 1,325,588 Shares of Hologic, Inc. (NASDAQ:HOLX)

Congress Asset Management Co. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 98.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,279 shares of the medical equipment provider's stock after selling 1,325,588 shares during the quarter. Congress Asset Management Co.'s holdings in Hologic were worth $1,678,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. General Partner Inc. bought a new stake in shares of Hologic during the fourth quarter valued at approximately $26,000. Groupama Asset Managment lifted its holdings in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 2,999 shares during the period. First Horizon Advisors Inc. lifted its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the period. Cromwell Holdings LLC lifted its holdings in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock valued at $44,000 after buying an additional 416 shares during the period. Finally, Covestor Ltd lifted its holdings in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider's stock valued at $56,000 after buying an additional 133 shares during the period. 94.73% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. William Blair restated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Finally, UBS Group increased their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $85.77.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Stock Up 0.2 %

Shares of HOLX stock traded up $0.15 during trading hours on Friday, hitting $64.47. 2,212,653 shares of the company were exchanged, compared to its average volume of 2,473,213. The business has a 50 day moving average of $69.91 and a two-hundred day moving average of $76.61. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52 week low of $62.69 and a 52 week high of $84.67. The company has a market capitalization of $14.47 billion, a PE ratio of 20.34, a PEG ratio of 2.13 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.